Breast Cancer Action

Breast Cancer Action
Name	Breast Cancer Action
Formation	1990
Headquarters	San Francisco, California
Region served	United States
Focus	Breast cancer advocacy, public health, environmental health

Breast Cancer Action is an American advocacy organization founded in 1990 that focuses on breast cancer prevention, health justice, and corporate accountability. The group has engaged with public health debates, pharmaceutical regulation, and environmental policy through campaigns, research, and grassroots organizing. Breast Cancer Action operates at the intersection of activism, science, and policy, interacting with institutions across the medical, regulatory, and non-profit sectors.

History

The organization was established in 1990 in San Francisco by activists responding to rising breast cancer incidence and perceived failures of established institutions such as National Cancer Institute, American Cancer Society, and local health departments. Early activities included protests at events hosted by Susan G. Komen for the Cure and critiques of media campaigns tied to corporations like Estée Lauder Companies and Yoplait. In the 1990s the group engaged with regulatory debates involving Food and Drug Administration, collaborated with environmental groups such as Environmental Working Group, and participated in coalitions that confronted chemical manufacturers including Dow Chemical Company and DuPont. Over subsequent decades Breast Cancer Action expanded its focus to include critiques of pharmaceutical practices linked to companies like Genentech and Pfizer, while also interacting with policy processes at Congress of the United States and regulatory review at Centers for Disease Control and Prevention.

Mission and Advocacy

Breast Cancer Action frames its mission around prevention, accountability, and health equity, positioning itself alongside organizations such as National Breast Cancer Coalition and SisterSong. The group advocates for stricter oversight by agencies like Environmental Protection Agency and Occupational Safety and Health Administration and supports legislation debated in the United States Congress that affects access to diagnostics and treatment. It frequently critiques partnerships between advocacy groups and corporations exemplified by past collaborations between Susan G. Komen for the Cure and cosmetic or retail companies such as Avon Products and Target Corporation. Breast Cancer Action also emphasizes disparities highlighted by research institutions including Johns Hopkins University and Harvard T.H. Chan School of Public Health, calling for community-centered approaches informed by activists associated with ACT UP and public-health practitioners tied to Kaiser Permanente.

Programs and Campaigns

Programs and campaigns have targeted corporate practices, screening policy, and environmental exposures. Notable initiatives have included consumer awareness campaigns critiquing promotional alliances involving Estée Lauder Companies and retail brands like Macy's, pressure campaigns on pharmaceutical pricing linked to firms like Roche/Genentech, and advocacy for regulatory action with agencies such as Food and Drug Administration and Environmental Protection Agency. The group has mounted signature drives and public actions modeled on tactics used by organizations like Greenpeace and ProPublica to influence reporting by outlets such as The New York Times and San Francisco Chronicle. Educational programming has drawn on scholarship from University of California, San Francisco and community health partnerships with clinics affiliated with Community Health Centers and academic hospitals like UCSF Medical Center.

Research and Policy Positions

Breast Cancer Action produces reports and position statements challenging narratives promoted by pharmaceutical companies including AstraZeneca and Novartis, and scrutinizes screening recommendations advanced by advisory bodies such as the United States Preventive Services Task Force. The organization has critiqued mammography campaigns and engaged with epidemiological literature from institutions like National Institutes of Health and Centers for Disease Control and Prevention to argue for prevention-oriented policies. It has pressed for chemical policy reform in dialogues with lawmakers in the United States Senate and agencies like the Environmental Protection Agency, referencing research on endocrine disruptors from labs at Massachusetts Institute of Technology and University of California, Berkeley. Breast Cancer Action also participates in coalition research with groups such as Commonweal and Breast Cancer Fund to highlight occupational exposures in industries represented by companies like 3M and Bayer.

Organizational Structure and Funding

The organization is structured with an executive team, a board of directors, and volunteer chapters, following governance practices similar to non-profits like American Civil Liberties Union and Planned Parenthood Federation of America. Funding sources have included individual donations, foundation grants from entities like Robert Wood Johnson Foundation and partnerships with philanthropic institutions comparable to Ford Foundation, while explicitly rejecting certain corporate sponsorships from companies such as Walt Disney Company or Estee Lauder in past campaigns. Financial reporting aligns with standards used by Internal Revenue Service filings for 501(c)(3) entities and the organization has engaged auditors and legal counsel in ways comparable to other advocacy groups like Human Rights Watch.

Criticism and Controversies

Breast Cancer Action has faced criticism from organizations and individuals endorsing different strategies, including disputes with Susan G. Komen for the Cure supporters and debates with some researchers at National Cancer Institute about screening guidance. Corporations targeted by the group, including Estée Lauder Companies and retailers such as Target Corporation, have disputed its claims. Some patient advocates and clinicians associated with institutions like Memorial Sloan Kettering Cancer Center and American Society of Clinical Oncology have critiqued the organization’s stance on screening and treatment messaging. The group’s refusal to accept certain corporate funding has prompted discussions in nonprofit oversight forums including panels convened by Independent Sector and critiques in media outlets such as The Washington Post.

Category:Breast cancer organizations